News and Insights from Our Multidisciplinary Team of Experts
Westminster, CO – November 8, 2018 — Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in...
November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA.
October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking...
October 30, 2018 – The true barrier for pathology AI is the business model, not the technology. To get pathology AI into the clinical laboratories, payers need to provide a value-based model that creates a viable business case. We estimate the U.S. anatomic pathology...
September 25, 2018 – Pathology AI Under a Central Lab Model: a cost-effective alternative and smart intermediate step for risk mitigation of a distributed medical device. A pathology AI system with an intended use for clinical diagnostics (Dx), prognostics (Px) or...
Hayward, CA and Westminster, CO – September 20, 2018 – Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA®...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insights while conserving...
EVENTS
View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...